Two investigator-initiated responder analysis trials of jaguar health's crofelemer show significant positive results for chronic refractory diarrhea in ibs-d: data accepted for presentation at american college of gastroenterology 2024 annual meeting

It is estimated that 10-15% of people in the united states have ibs san francisco, ca / accesswire / august 1, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") family company napo pharmaceuticals ("napo") today announced that the results of two independent investigator-initiated studies of crofelemer, napo's novel, plant-based oral prescription drug, showed a benefit in patients with chronic refractory diarrhea and have been accepted for poster presentations at the american college of gastroenterology annual scientific meeting, which takes place october 25-30, 2024 at the pennsylvania convention center in philadelphia. "we are very excited that crofelemer continues to demonstrate clinical robustness in responder analysis trials for multiple gastroenterological conditions - including functional diarrhea and chronic idiopathic diarrhea.
JAGX Ratings Summary
JAGX Quant Ranking